{
  "docId": "019de076-b5af-740f-a5f5-cc716fe64761",
  "docSlug": "e5f34198aff4080f2687fe569caff4c0",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 33,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes a personal testimonial/case study image of a patient (Shay) to humanize the disease.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b5af-740f-a5f5-cc716fe64761/5",
  "deckHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761",
  "deckJsonHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761.json",
  "deckAnchorHref": "/decks/019de076-b5af-740f-a5f5-cc716fe64761#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.28,
        "w": 0.43,
        "x": 0.35,
        "y": 0.1
      },
      "kind": "image",
      "text": "Shay: Dec. 2010 / Shay: Mar. 2013",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6973ec98-4ece-48ef-a0a6-33c51a5e5fdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.63,
        "y": 0.65
      },
      "kind": "metric",
      "text": "~24% Growth in Patients by 2040 in the US and EU",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32eb1253-6fde-4572-a3fa-69dd50d7d955",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.63,
        "y": 0.42
      },
      "kind": "metric",
      "text": ">80,000 ALS Patients in NeuroSense’s planned target market",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65371050-0937-4aa1-b1f0-8274efcaf915",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.35,
        "y": 0.42
      },
      "kind": "metric",
      "text": "+5,000 New cases of ALS each year (US)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd41dd25-1fe7-4739-804c-2c3dab9697ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.35,
        "y": 0.65
      },
      "kind": "metric",
      "text": "~$3B Annual Market Opportunity",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe0805ac-0c21-446e-8025-ed150743fd60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.09,
        "y": 0.34
      },
      "kind": "paragraph",
      "text": "is an incurable neurodegenerative disease, causing complete paralysis and ultimately death within 2-5 years from diagnosis",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b22fc4b3-4a11-437e-a325-fa14fc4225cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.08,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "1 Johns Hopkins Medicine 2 Projected increase in amyotrophic lateral sclerosis from 2015 to 2040, Nature Communications, 2016 3 Management estimate",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91f5ec0b-407a-4c34-b92c-3006354a0bf4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.15,
        "x": 0.09,
        "y": 0.265
      },
      "kind": "title",
      "text": "ALS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69f92690-4eda-45d4-babf-4e510459bbbe",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "d8c7990f-d395-402e-8b88-8e86addf0b80",
      "evidence": "is an incurable neurodegenerative disease, causing complete paralysis and ultimately death within 2-5 years from diagnosis",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 5,
      "beatId": "07446762-8c93-42f3-9372-d09450c844ce",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document identifies ALS as a debilitating disease with limited treatment options (p5).",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}